Home
The U.S. FDA Approved BridgeBio Pharma Product Attruby to Treat Adults with ATTR-CM to Reduce Cardiovascular Death and Hospitalization

The U.S. FDA Approved BridgeBio Pharma Product Attruby to Treat Adults with ATTR-CM to Reduce Cardiovascular Death and Hospitalization

Impacting News November 25, 2024

BridgeBio Pharma in the NEWS

BridgeBio Pharma (BBIO) focused on genetic diseases, announced that the United States FDA approved Attruby™ (acoramidis), an orally administered near-complete stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM. The aim is to reduce cardiovascular death and cardiovascular-related hospitalization.

The approval is based on positive results seen in the ATTRibute-CM Phase 3 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
November 25, 2024

Other Articles